Fasciola gigantica fatty acid binding protein (FABP) as a prophylactic agent against Schistosoma mansoni infection in CD1 mice

Korean Journal of Parasitology

Volumn 50, Issue 1, 2012, Pages 37-43

  Aly, Ibrahim Rabia ^a   Diab, M ^a   El Amir, A M ^b   Hendawy, M ^a   Kadry, S ^b  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

FABP; Fasciola gigantica; Heterologous protection; Schistosoma mansoni; Th1 Th2 immunity

Indexed keywords

2 DIETHYLAMINOETHANOL; AMMONIUM SULFATE; FATTY ACID BINDING PROTEIN; FREUND ADJUVANT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B; SEPHADEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELLULAR IMMUNITY; CERCARIA; CONTROLLED STUDY; DRUG PURIFICATION; FASCIOLA GIGANTICA; FEMALE; GEL FILTRATION CHROMATOGRAPHY; IMMUNIZATION; INTESTINE; LIVER GRANULOMA; LIVER PARENCHYMA; MOUSE; MOUSE STRAIN; NONHUMAN; SCHISTOSOMIASIS MANSONI; TH1 CELL; TH2 CELL; WORM INFECTION;

ANIMALS; ANTIBODIES, HELMINTH; FASCIOLA; FATTY ACID-BINDING PROTEINS; FEMALE; HELMINTH PROTEINS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED STRAINS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

FASCIOLA GIGANTICA; MUS; SCHISTOSOMA MANSONI;

EID: 84858993999     PISSN: 00234001     EISSN: 17380006     Source Type: Journal    
DOI: 10.3347/kjp.2012.50.1.37     Document Type: Article

References (34)

1. King CH. Toward the elimination of schistosomiasis. N Engl J Med 2009; 360: 106-109.
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-425.
3. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86: 125-139.
4. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-242.
5. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21: 143-149.
6. Wilson RA, Coulson PS. Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz 2006; 101: S13-20.
7. Hillyer GV. Fasciola antigens as vaccines against fascioliasis and schistosomiasis. J Helminthol 2005; 79: 241-247.
8. Abán JL, Ramajo V, Arellano JL, Oleaga A, Hillyer GV, Muro A. A fatty acid binding protein from Fasciola hepatica induced protection in C57/BL mice from challenge infection with Schistosoma bovis. Vet Parasitol 1999; 83: 107-121.
9. Sirisriro A, Grams R, Vichasri-Grams S, Ardseungneon P, Pankao V, Meepool A, Chaithirayanon K, Viyanant V, Tan-Ariya P, Upatham ES, Sobhon P. Production and characterization of a monoclonal antibody against recombinant fatty acid binding protein of Fasciola gigantica. Vet Parasitol 2002; 105: 119-129.
10. Nessim NG, Hassan SI, William S, el-Baz H. Effect of the broad spectrum anthelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice. Arzneimittelforschung 2000; 50: 1129-1133.
11. Timanova A, Müller S, Marti T, Bankov I, Walter RD. Ascaridia galli fatty acid-binding protein, a member of the nematode polyprotein allergens family. Eur J Biochem 1999; 261: 569-576.
12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
13. Duvall RH, DeWitt WB. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 1967; 16: 483-486.
14. Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 1968; 39: 328-331.
15. Pellegrino J, Oliveira CA, Faria J, Cunha AS. New approach to the screening of drugs in experimental Schistosomiasis mansoni in mice. Am J Trop Med Hyg 1962; 11: 201-215.
16. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971; 8: 871-874.
17. von Lichtenberg. Host response to eggs of S. mansoni. I. Granuloma formation in the unsensitized laboratory mouse. Am J Pathol 1962; 41: 711-731.
18. Cherfas J. New hope for vaccine against schistosomiasis. Science 1991; 251: 630-631.
19. McManus DP. A vaccine against Asian schistosomiasis: the story unfolds. Int J Parasitol 2000; 30: 265-271.
20. Hillyer GV. Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Mem Inst Oswaldo Cruz 1995; 90: 249-253.
21. Janecharut T, Kitikoon V, Usawattanakul W, Sornmani S. Investigation on immunity induced by Schistosoma spindale against S. mekongi in experimental mice. Southeast Asian J Trop Med Public Health 1988; 19: 123-129.
22. Agnew AM, Murare HM, Doenhoff MJ. Specific cross-protection between Schistosoma bovis and S. haematobium induced by highly irradiated infections in mice. Parasite Immunol 1989; 11: 341-349.
23. Dean DA, Mangold BL, Harrison RA, Ricciardone MD. Homologous and heterologous protective immunity to Egyptian strains of Schistosoma mansoni and S. haematobium induced by ultraviolet-irradiated cercariae. Parasite Immunol 1996; 18: 403-410.
24. Rabia I, Ali E, Hassan E, Salah F, El-Dafrawy T. Intraperitoneal injection of Echinostome antigens confers resistance to schistosomal infection in murine model. New Egypt J Med 2007; 36: 25-31.
25. Siles-Lucas M, Uribe N, López-Abán J, Vicente B, Orfao A, Nogal-Ruiz JJ, Feliciano AS, Muro A. The Schistosoma bovis Sb14-3-3zeta recombinant protein cross-protects against Schistosoma mansoni in BALB/c mice. Vaccine 2007; 25: 7217-7223.
26. Hamed MA. Excretory-secretory product of Fasciola hepatica worm protects against Schistosoma mansoni infection in mice. Indian J Exp Biol 2006; 44: 554-561.
27. Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14: 15-17.
28. Pfeifhofer C, Gruber T, Letschka T, Thuille N, Lutz-Nicoladoni C, Hermann-Kleiter N, Braun U, Leitges M, Baier G. Defective IgG2a/2b class switching in PKC alpha-/-mice. J Immunol 2006; 176: 6004-6011.
29. Nascimento E, Leão IC, Pereira VR, Gomes YM, Chikhlikar P, August T, Marques E, Lucena-Silva N. Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis. Mem Inst Oswaldo Cruz 2002; 97: S105-109.
30. Dupré, Herv M, Schacht AM, Capron A, Riveau G. Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment. J Infect Dis 1999; 180: 454-463.
31. Ramos HR, Miyasato PA, Ramos CR, de Mattos Arêas AP, Kawano T, Ho PL. A genetic fusion between Sm14 and CTB does not reduce Schistosoma mansoni worm burden on intranasally immunized BALB/c mice. J Vaccines Vaccin 2010; 1: 111.
32. Pearce EJ, James SL, Hieny S, Lanar DE, Sher A. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc Natl Acad Sci U S A 1988; 85: 5678-5682.
33. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, Caliari MV, Almeida GT, Venancio TM, Verjovski-Almeida S, Oliveira SC. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2008; 2: e308.
34. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Pompa J, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21: 2882-2889.